Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Amgen/NPS Pharmaceuticals

Executive Summary

Amgen/NPS Pharmaceuticals: Sign binding letter of intent to collaborate in developing and commercializing NPS' Norcalcin (NPS R-568) and other proprietary calcium receptor agonists for treatment of hyperparathyroidism. Amgen will have exclusive worldwide rights (excluding Japan, China, Korea and Taiwan, covered by NPS' corporate partnership with Kirin) to develop and sell Norcalcin. It will pay NPS initial license fee of $10 mil., milestone payments of up to $26 mil. and royalties on sales, and purchase 1 mil. shares for $7.5 mil. Norcalcin is currently in Phase I/II clinical trials...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027415

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel